Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance

MT Newswires Live

Feb 06

Racura Oncology (ASX:RAC) is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.

It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.

The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609555609"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609555609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609555609?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 13:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609555609","market":"hk","top_or_hot":-1,"title":"Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.</p><p>It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.</p><p>The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-06 13:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.</p><p>It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.</p><p>The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2609555609","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609555609","pubTimestamp":1770354705,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Racura Oncology提议在发行行政监督后选择性回购、注销股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Racura Oncology (ASX:RAC) is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}